phase 3 (of a clinical trial)sān qī三期clinical triallínchuáng shìyàn临床试验to confirm / to provezhèngshí证实new type / novelxīn xíng新型antihypertensive drugjiàngyā yào降压药baxdrostat (drug name)Bā shā sī tā巴沙司他therapeutic efficacyliáoxiào疗效significant / markedxiǎnzhù显著。
April 4, 2026 at 2:00 PM
New Words
News in English
Lifestyle & CulturePhase 3 Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Patients Resistant to Standard Treatment
A phase 3 clinical trial in the New England Journal of Medicine shows baxdrostat, an aldosterone synthase inhibitor, significantly lowers blood pressure in resistant hypertension patients, with around 40 percent reaching healthy levels.
The latest issue of the New England Journal of Medicine published the phase 3 clinical trial results for the new antihypertensive drug baxdrostat. The trial enrolled 794 patients with treatment-resistant or uncontrolled hypertension, randomly assigned to receive 1 milligram, 2 milligrams of baxdrostat, or placebo for a 12-week course. Results showed that patients taking 1 milligram had average systolic blood pressure decrease of 14.5 mmHg, and those taking 2 milligrams decreased 15.7 mmHg, both significantly better than the placebo group's 5.8 mmHg. Notably, approximately 40% of treated patients' blood pressure recovered to healthy levels, far exceeding the placebo group's less than 20% proportion. Baxdrostat is an aldosterone synthase inhibitor that lowers blood pressure by inhibiting adrenal secretion of the aldosterone hormone, with a mechanism completely different from existing first-line antihypertensive drugs. Researchers noted this target is particularly effective for patients whose hypertension is caused by excessive aldosterone secretion, a considerable proportion of the treatment-resistant hypertension population. Regarding safety, a small number of participants developed hyperkalemia, requiring clinical monitoring. The US FDA has placed the drug in priority review, with approval targeted for the second quarter of 2026. Given the global hypertension patient population exceeds one billion, with considerable treatment-resistant cases, these trial results are viewed by the medical community as an important breakthrough.
More in Lifestyle & Culture
the Arctic / ArcticBěijí北极permafrostyǒngjiǔ dòng tǔ永久冻土to accelerate / to speed upjiāsù加速to melt / to thawrónghuà融化，ancient / age-oldgǔlǎo古老organic carbonyǒujī tàn有机碳to flow intoliúrù流入ocean / seahǎiyáng海洋to raise / to triggeryǐnfā引发climateqìhòu气候warning / alertjǐngshì警示。
Thawing Arctic Permafrost Releases Ancient Carbon Into Oceans, Raising Climate Fears
newxīnxíng新型wearablekěchuāndài可穿戴patchtiēpiàn贴片acceleratejiāokuài加快peoplerénmen人们enterjìnrù进入deepshēndù深度sleepshuìmián睡眠。
New Wearable Patch Accelerates Entry Into REM Sleep by 43 Minutes
total solar eclipserìquánshí日全食todayjīnrì今日to cross / to pass throughchuānyuè穿越IcelandBīngdǎo冰岛andyǔ与SpainXībānyá西班牙。
Total Solar Eclipse Crosses Iceland and Spain Today
ChinaZhōng guó中国to be unearthed / to excavatechū tǔ出土the Warring States periodZhàn guó战国bronzeqīng tóng青铜wine vesseljiǔ qì酒器，containing insidenèi cáng内藏dating back from nowjù jīn距今approximatelyyuē约2,300 years2300 nián2300年(modifier particle)de的ancientgǔ dài古代fine wineměi jiǔ美酒。
Warring States Bronze Vessel Containing 2,300-Year-Old Wine Unearthed in China